Soleno Therapeutics Stock Today

SLNO Stock  USD 45.85  1.11  2.36%   

Performance

5 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 48

 
High
 
Low
About Average
Soleno Therapeutics is selling at 45.85 as of the 23rd of July 2024; that is 2.36 percent decrease since the beginning of the trading day. The stock's open price was 46.96. Soleno Therapeutics has 48 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Soleno Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of November 2014
Category
Healthcare
Classification
Health Care
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. The company has 36.86 M outstanding shares of which 3.51 M shares are at this time shorted by private and institutional investors with about 5.96 trading days to cover. More on Soleno Therapeutics

Moving together with Soleno Stock

  0.68EWTX Edgewise TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Soleno Stock Highlights

ESG Sustainability
Environmental
Governance
Social
PresidentAnthony Wondka
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current LiabilitiesM11.5 M
Way Down
Pretty Stable
Non Current Liabilities Total10.1 M11.7 M
Fairly Down
Slightly volatile
Total Assets189.7 M180.7 M
Sufficiently Up
Slightly volatile
Total Current Assets179.9 M171.4 M
Sufficiently Up
Slightly volatile
Debt Levels
Soleno Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Soleno Therapeutics' financial leverage. It provides some insight into what part of Soleno Therapeutics' total assets is financed by creditors.
Liquidity
Soleno Therapeutics currently holds 403 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Soleno Therapeutics has a current ratio of 3.36, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Soleno Therapeutics' use of debt, we should always consider it together with its cash and equity.

Depreciation

1.26 Million
Soleno Therapeutics (SLNO) is traded on NASDAQ Exchange in USA. It is located in 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 and employs 33 people. Soleno Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.73 B. Soleno Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.86 M outstanding shares of which 3.51 M shares are at this time shorted by private and institutional investors with about 5.96 trading days to cover. Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Soleno Therapeutics Probability Of Bankruptcy
Ownership Allocation
The majority of Soleno Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Soleno Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Soleno Therapeutics. Please pay attention to any change in the institutional holdings of Soleno Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Soleno Ownership Details

Soleno Stock Institutional Holders

InstituionRecorded OnShares
Wellington Management Company Llp2024-03-31
353.5 K
Ally Bridge Group (ny) Llc2024-03-31
336.5 K
Pictet Asset Manangement Sa2024-03-31
333.9 K
Blackrock Inc2024-03-31
326.3 K
Amvescap Plc.2024-03-31
320 K
Emerald Advisers, Llc2024-03-31
300.4 K
Emerald Mutual Fund Advisers Trust2024-03-31
231.8 K
Samlyn Capital, Llc2024-03-31
218.9 K
Goldman Sachs Group Inc2024-03-31
211.9 K
Vivo Capital, Llc2024-03-31
8.4 M
The Carlyle Group Inc2024-03-31
4.1 M
View Soleno Therapeutics Diagnostics

Soleno Therapeutics Historical Income Statement

At this time, Soleno Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 23rd of July 2024, Research Development is likely to grow to about 26.4 M, while Interest Expense is likely to drop about 282.1 K. View More Fundamentals

Soleno Stock Against Markets

Soleno Therapeutics Corporate Management

Kristen MSVice OperationsProfile
Dr MBASenior DevelopmentProfile
James MacKanessChief OfficerProfile
Meredith MBAChief OfficerProfile
Anish MDCEO and PresidentProfile

Additional Information and Resources on Investing in Soleno Stock

When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.07)
Return On Assets
(0.36)
Return On Equity
(0.71)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.